MA37992B1 - Composes inhibiteurs de protéase ns3 pour une utilisation dans le traitement de l’infection par le virus de l'hépatite c. - Google Patents

Composes inhibiteurs de protéase ns3 pour une utilisation dans le traitement de l’infection par le virus de l'hépatite c.

Info

Publication number
MA37992B1
MA37992B1 MA37992A MA37992A MA37992B1 MA 37992 B1 MA37992 B1 MA 37992B1 MA 37992 A MA37992 A MA 37992A MA 37992 A MA37992 A MA 37992A MA 37992 B1 MA37992 B1 MA 37992B1
Authority
MA
Morocco
Prior art keywords
hepatitis
treatment
protease inhibitor
virus infection
inhibitor compounds
Prior art date
Application number
MA37992A
Other languages
English (en)
Other versions
MA37992A1 (fr
Inventor
Li-Qiang Sun
Eric Mull
Eric P Gillis
Michael S Bowsher
Qian Zhao
Kishore V Renduchintala
Kandhasamy Sarkunam
Pulicharla Nagalakshmi
Suresh P V K Babu
Paul Michael Scola
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA37992A1 publication Critical patent/MA37992A1/fr
Publication of MA37992B1 publication Critical patent/MA37992B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)

Abstract

La présente invention concerne des inhibiteurs du virus de l'hépatite c ayant la formule générale (i). La présente invention concerne en outre des compositions comprenant les composés et des méthodes permettant d'utiliser les composés afin d'inhiber le vhc.
MA37992A 2012-10-19 2012-10-19 Composes inhibiteurs de protéase ns3 pour une utilisation dans le traitement de l’infection par le virus de l'hépatite c. MA37992B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/061094 WO2014062196A1 (fr) 2012-10-19 2012-10-19 Inhibiteurs du virus de l'hépatite c

Publications (2)

Publication Number Publication Date
MA37992A1 MA37992A1 (fr) 2018-02-28
MA37992B1 true MA37992B1 (fr) 2018-09-28

Family

ID=47144142

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37992A MA37992B1 (fr) 2012-10-19 2012-10-19 Composes inhibiteurs de protéase ns3 pour une utilisation dans le traitement de l’infection par le virus de l'hépatite c.

Country Status (29)

Country Link
US (1) US9499550B2 (fr)
EP (1) EP2909205B1 (fr)
JP (1) JP6154474B2 (fr)
KR (1) KR20150074051A (fr)
CN (1) CN104918941A (fr)
AR (1) AR088768A1 (fr)
AU (1) AU2012392557B2 (fr)
BR (1) BR112015007879A2 (fr)
CA (1) CA2888755A1 (fr)
CY (1) CY1118729T1 (fr)
DK (1) DK2909205T3 (fr)
EA (1) EA025560B1 (fr)
ES (1) ES2613766T3 (fr)
HR (1) HRP20161694T1 (fr)
HU (1) HUE031625T2 (fr)
IL (1) IL238286B (fr)
LT (1) LT2909205T (fr)
MA (1) MA37992B1 (fr)
MX (1) MX360452B (fr)
PH (1) PH12015500814A1 (fr)
PL (1) PL2909205T3 (fr)
PT (1) PT2909205T (fr)
RS (1) RS55592B1 (fr)
SG (1) SG11201502802PA (fr)
SI (1) SI2909205T1 (fr)
SM (2) SMT201700117T1 (fr)
TW (1) TWI570125B (fr)
WO (1) WO2014062196A1 (fr)
ZA (1) ZA201503458B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH074495B2 (ja) 1992-08-07 1995-01-25 日本エアーテック株式会社 フィルターアタッチメント
US9643999B2 (en) * 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2914613B1 (fr) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2914614B1 (fr) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2964664B1 (fr) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
JP2020193181A (ja) * 2019-05-30 2020-12-03 東ソー株式会社 芳香族ニトリル化合物の製造方法
US12441762B2 (en) * 2019-06-07 2025-10-14 University Of Massachusetts Hepatitis c virus NS3/4A protease inhibitors
CN112094229B (zh) * 2020-10-12 2022-11-22 苏州康润医药有限公司 6-（三氟甲基）异喹啉-5-醇的合成方法
CN114805204B (zh) * 2022-04-01 2023-09-15 云南师范大学 一种制备4-碘异喹啉-1(2h)-酮类化合物的方法

Family Cites Families (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475255A3 (en) 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
MXPA03004299A (es) 2000-11-20 2004-02-12 Bristol Myers Squibb Co Inhibidores de tripeptido de hepatitis c.
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (fr) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques qui agissent contre le virus de l'hepatite c
CA2370396A1 (fr) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
CA2369970A1 (fr) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
AU2003248535A1 (en) 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
PL215228B1 (pl) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
ES2315568T3 (es) 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CN1771050A (zh) * 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
JP4550824B2 (ja) 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎抑制化合物
DE602004029866D1 (de) 2003-03-05 2010-12-16 Boehringer Ingelheim Pharma Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
RS20050741A (sr) 2003-04-02 2007-06-04 Boehringer Ingelheim International Gmbh., Farmaceutske kompozicije za inhibitore virusne proteaze hepatitisa c
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
WO2004093798A2 (fr) 2003-04-18 2004-11-04 Enanta Pharmaceuticals, Inc. Composes macrocycliques de quinoxalinyle inhibant les serine proteases de l'hepatite c
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
WO2004113365A2 (fr) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Inhibiteurs de la tripeptide hepatite c serine protease
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
EP1673385B1 (fr) * 2003-09-22 2011-03-02 Boehringer Ingelheim International GmbH Peptides macrocycliques actifs contre le virus de l'hepatite c
NZ546663A (en) 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005037214A2 (fr) 2003-10-14 2005-04-28 Intermune, Inc. Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MXPA06005683A (es) 2003-11-20 2006-12-14 Schering Corp Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c.
WO2005070955A1 (fr) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Peptides macrocycliques actifs contre le virus de l'hepatite c
ES2336009T3 (es) 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
ES2338666T3 (es) 2004-03-15 2010-05-11 Boehringer Ingelheim International Gmbh Procedimiento para la preparacion de dipeptidos macrociclicos adecuados para el tratamiento de infecciones viricas de la hepatitis c.
EP1749007A2 (fr) 2004-03-30 2007-02-07 Intermune, Inc. Composes macrocycliques inhibiteurs de replication virale
WO2006016930A2 (fr) 2004-05-14 2006-02-16 Intermune, Inc. Procédés de traitement de l’infection vhc
EP1753775B1 (fr) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Processus de preparation d'inhibiteurs de protease hcv acyclique
JP4914348B2 (ja) 2004-06-28 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
KR20070034119A (ko) 2004-07-16 2007-03-27 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
JP4914355B2 (ja) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
MX2007002371A (es) 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
US7375218B2 (en) 2004-09-17 2008-05-20 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic HCV protease inhibitors
WO2007001406A2 (fr) 2004-10-05 2007-01-04 Chiron Corporation Composes macrocycliques contenant un aryle
MX2007004783A (es) 2004-10-21 2007-05-11 Pfizer Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103172697A (zh) 2005-03-08 2013-06-26 贝林格尔.英格海姆国际有限公司 制备大环化合物的方法
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20060276407A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
WO2006130666A2 (fr) 2005-06-02 2006-12-07 Schering Corporation Medicaments et procedes destines a combiner un inhibiteur de protease hcv et un competiteur akr
WO2006130552A2 (fr) 2005-06-02 2006-12-07 Schering Corporation Methodes de traitement du virus de l'hepatite c
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
JP2008545748A (ja) 2005-06-02 2008-12-18 シェーリング コーポレイション Ｃ型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物
US20060281689A1 (en) 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US7772178B2 (en) 2005-06-02 2010-08-10 Schering Corporation Pharmaceutical formulations and methods of treatment using the same
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
US20070004635A1 (en) 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
US20080200497A1 (en) 2005-07-20 2008-08-21 Bailey Murray D Hepatitis C Inhibitor Peptide Analogs
EP2305696A3 (fr) 2005-07-25 2011-10-12 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
EP1919904B1 (fr) 2005-07-29 2014-01-08 Janssen R&D Ireland Inhibiteurs macrocycliques du virus de l'hépatite c
BRPI0614637A2 (pt) 2005-07-29 2011-04-12 Tibotec Pharm Ltd inibidores macrocìclicos do vìrus da hepatite c
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
EP1910347A2 (fr) 2005-07-29 2008-04-16 Medivir Ab Inhibiteurs macrocycliques du virus de l'hepatite c
AR055105A1 (es) 2005-07-29 2007-08-08 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
RU2436787C2 (ru) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
WO2007014922A1 (fr) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
ATE496042T1 (de) 2005-07-29 2011-02-15 Tibotec Pharm Ltd Makrocyclische inhibitoren des hepatitis-c-virus
US8278322B2 (en) 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2007016476A2 (fr) 2005-08-01 2007-02-08 Phenomix Corporation Inhibiteurs de la sérine protéase de l'hépatite c et emploi desdits inhibiteurs
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP1934243B1 (fr) 2005-09-09 2011-05-25 Boehringer Ingelheim International GmbH Reaction de fermeture de cycle par metathese pour preparation de peptides macrocycliques
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007082131A1 (fr) 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Procédé de synthèse d’hétérocycles hydroxy-substitués
JP2009528353A (ja) 2006-03-03 2009-08-06 シェーリング コーポレイション Ｈｃｖのプロテアーゼ阻害剤およびｉｒｅｓ阻害剤の医薬的組み合わせ
WO2007120595A2 (fr) 2006-04-11 2007-10-25 Novartis Ag Composés organiques et leurs utilisations
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US20070281884A1 (en) 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
UY30437A1 (es) 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US7893264B2 (en) 2006-07-07 2011-02-22 Gilead Sciences, Inc. Antiviral phosphinate compounds
WO2008008776A2 (fr) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
ES2448494T3 (es) 2006-07-13 2014-03-14 Achillion Pharmaceuticals, Inc. Péptidos de 4-amino-4-oxobutanoilo en calidad de inhibidores de la replicación viral
WO2008019303A2 (fr) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Inhibiteurs de sérine protéases de l'hépatite c macrocycliques de type pyridazinonyle
US20090035267A1 (en) 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
CN101674844A (zh) 2006-08-04 2010-03-17 英安塔制药有限公司 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
WO2008021960A2 (fr) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Inhibiteurs triazolyle macrocycliques de la sérine protéase de l'hépatite c
US7605126B2 (en) 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US20080038225A1 (en) 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US20090035268A1 (en) 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
WO2008022006A2 (fr) 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Inhibiteurs de protéase du virus de l'hépatite c arylalcoxyle
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CN101583372A (zh) 2006-10-24 2009-11-18 默克公司 Hcv ns3蛋白酶抑制剂
CA2667165A1 (fr) 2006-10-24 2008-05-02 Merck & Co., Inc. Inhibiteurs de la protease hcv ns3
WO2008057208A2 (fr) 2006-10-27 2008-05-15 Merck & Co., Inc. Inhibiteurs de protéase ns3 du vhc
JP5268927B2 (ja) 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107623A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080107625A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
WO2008057995A2 (fr) 2006-11-02 2008-05-15 Taigen Biotechnology Co., Ltd. Inhibiteurs de protéase de vhc
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (fr) 2006-11-16 2008-06-12 Phenomix Corporation Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008059046A1 (fr) 2006-11-17 2008-05-22 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
US20100323953A1 (en) 2007-01-08 2010-12-23 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
US20080207528A1 (en) 2007-02-01 2008-08-28 Syaulan Yang Hcv protease inhibitors
SI2118098T1 (sl) 2007-02-01 2015-01-30 Janssen R&D Ireland Polimorfne oblike makrocikličnega inhibitorja HCV
RU2483067C2 (ru) 2007-02-01 2013-05-27 Тиботек Фармасьютикалз Лтд. Способы и промежуточные продукты для получения макроциклического ингибитора протеазы вируса гепатита с
MX2009008541A (es) 2007-02-08 2009-08-18 Tibotec Pharm Ltd Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
RU2481340C2 (ru) 2007-02-08 2013-05-10 Тиботек Фармасьютикалз Лтд. Пиримидин-замещенные макроциклические ингибиторы hcv
WO2008096002A1 (fr) 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Phosphonates et amidophosphates macrocycliques inhibiteurs du vhc
JP2010518128A (ja) 2007-02-16 2010-05-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ｎｓ３プロテアーゼのインヒビター
BRPI0807887A2 (pt) 2007-02-20 2014-06-17 Novartis Ag Compostos macrocíclicos como inibidores de hcv ns3 protease.
EP2125113A2 (fr) 2007-02-26 2009-12-02 Achillion Pharmaceuticals, Inc. Peptides substitués par une amine tertiaire utiles comme inhibiteurs de la réplication du virus de l'hépatite c
ES2355437T3 (es) 2007-04-24 2011-03-25 F. Hoffmann-La Roche Ag Procedimiento para un intermediario de inhibidores de proteasa del vhc.
US20080292587A1 (en) 2007-04-26 2008-11-27 Ying Sun Oximyl dipeptide hepatitis c protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
WO2008134395A1 (fr) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Inhibiteurs macrocycliques azapeptidiques des protéases à sérine du virus de l'hépatite c
WO2008134397A1 (fr) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Inhibiteurs à base d'aza-tripeptide de la sérine protéase de l'hépatite c
WO2008137779A2 (fr) * 2007-05-03 2008-11-13 Intermune, Inc. Inhibiteurs macrocycliques innovants de la réplication du virus de l'hépatite c
CA2686546A1 (fr) 2007-05-10 2008-11-20 Intermune, Inc. Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
NZ582096A (en) 2007-06-29 2012-05-25 Gilead Sciences Inc Antiviral compounds that inhibit hepatitis c virus (hcv)
AR068794A1 (es) 2007-06-29 2009-12-09 Gilead Sciences Inc Compuestos antivirales
AR067180A1 (es) 2007-06-29 2009-09-30 Gilead Sciences Inc Compuestos antivirales
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
WO2009014730A1 (fr) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase
KR101396696B1 (ko) 2007-10-10 2014-05-16 노파르티스 아게 스피로피롤리딘, 및 ｈｃｖ 및 ｈｉｖ 감염에 대한 그의 용도
WO2009053828A2 (fr) 2007-10-22 2009-04-30 Enanta Pharmaceuticals, Inc. Inhibiteurs p3-hydroxyamino macrocycliques des sérine protéases de l'hépatite c
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
JP2011503201A (ja) 2007-11-14 2011-01-27 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状テトラゾリルｃ型肝炎セリンプロテアーゼ阻害剤
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8030307B2 (en) 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
CA2708150A1 (fr) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Composes a base de tripeptides fluores inhibant la serine protease du vhc
MX2010006209A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Derivados de quinoxalinilo.
WO2009073713A1 (fr) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Dérivés macrocycliques d'oximyle
WO2009076166A2 (fr) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Inhibiteurs oximyles de la sérine protéase de vhc
CA2708047A1 (fr) 2007-12-06 2009-06-11 Enanta Pharmaceuticals, Inc. Procede de preparation d'inhibiteurs de protease de l'hepatite c oximyle macrocycliques
WO2009079353A1 (fr) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Inhibiteurs macrocycliques contenant du triazole des protéases à sérine du vhc
JP2011506472A (ja) 2007-12-14 2011-03-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状オキシミルｃ型肝炎セリンプロテアーゼ阻害剤
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
CN104557880A (zh) 2007-12-21 2015-04-29 阿维拉制药公司 Hcv蛋白酶抑制剂和其用途
WO2009082697A1 (fr) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Inhibiteurs de hcv protéase et leurs utilisations
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
AU2008340430B2 (en) 2007-12-21 2013-01-24 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
JP2011510926A (ja) 2008-01-24 2011-04-07 エナンタ ファーマシューティカルズ インコーポレイテッド ヘテロアリール含有トリペプチドｈｃｖセリンプロテアーゼ阻害剤
CA2713005A1 (fr) 2008-01-24 2009-07-30 Enanta Pharmaceuticals, Inc. Tripeptides difluores en tant qu'inhibiteurs de la serine protease du vhc
CA2714604A1 (fr) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Inhibiteurs macrocycliques de la protease ns3 du vhc
CA2719008A1 (fr) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Composes macrocycliques fluores en tant qu'inhibiteurs du virus de l'hepatite c
WO2009142842A2 (fr) 2008-04-15 2009-11-26 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la réplication du virus de l’hépatite c
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102014911A (zh) 2008-04-28 2011-04-13 默沙东公司 Hcv ns3蛋白酶抑制剂
WO2009134987A1 (fr) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Composés macrocycliques contenant du difluorométhyle comme inhibiteurs du virus de l’hépatite c
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102046648A (zh) 2008-05-29 2011-05-04 百时美施贵宝公司 丙型肝炎病毒抑制剂
ES2392611T3 (es) 2008-07-22 2012-12-12 Merck Sharp & Dohme Corp. Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
EP2323981B1 (fr) 2008-08-07 2014-03-12 F. Hoffmann-La Roche AG Procédé pour la préparation d'un macrocycle
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010033466A1 (fr) 2008-09-16 2010-03-25 Phenomix Corporation Inhibiteurs macrocycliques de la protéase du virus de l'hépatite c
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
WO2010031832A2 (fr) 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Combinaisons synergiques d'un inhibiteur macrocyclique de hcv et d'un dérivé d'acide thiophène-2-carboxylique
EP2344487A4 (fr) 2008-09-23 2012-03-21 Boehringer Ingelheim Int Composés inhibiteurs de l'hépatite c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP5689810B2 (ja) 2008-11-20 2015-03-25 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｃ型肝炎ウイルス用の環状カルボキサミド化合物およびその類似体
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20100152103A1 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
ES2527166T3 (es) 2008-12-10 2015-01-21 Achillion Pharmaceuticals, Inc. Nuevos péptidos de 4-amino-4-oxobutanoílo como inhibidores de la replicación viral
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2011006631A (es) 2008-12-19 2011-09-06 Gilead Sciences Inc Inhibidores de proteasa ns3 del virus hcv.
AU2009330333A1 (en) 2008-12-22 2011-07-07 Gilead Sciences, Inc. Antiviral compounds
JP2012516351A (ja) 2009-01-30 2012-07-19 アナコール ファーマシューティカルズ，インコーポレーテッド 化合物
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
CA2761650C (fr) 2009-05-13 2015-05-26 Enanta Pharmaceuticals, Inc. Composes macrocycliques comme inhibiteurs du virus de l'hepatite c
CN101921308A (zh) 2009-06-16 2010-12-22 上海唐润医药科技有限公司 具有抗hcv活性的化合物及其用途
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
PE20120322A1 (es) 2009-07-07 2012-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
EP2470189A4 (fr) 2009-08-27 2013-01-23 Merck Sharp & Dohme Procédés de préparation d inhibiteurs de protéase du virus de l hépatite c
EP2477980B1 (fr) 2009-09-15 2016-06-08 Taigen Biotechnology Co., Ltd. Inhibiteurs de protéases de vhc
CN105001302A (zh) 2009-09-28 2015-10-28 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
MX2012003171A (es) 2009-09-28 2012-04-11 Hoffmann La Roche Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
TW201116540A (en) 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US9193740B2 (en) 2009-10-19 2015-11-24 Enanta Pharmaceuticals, Inc. Bismacrocyclic compounds as hepatitis C virus inhibitors
WO2011063502A1 (fr) 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Composés inhibiteurs de l'hépatite c
JP2013511561A (ja) 2009-11-24 2013-04-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
MX2012007076A (es) 2009-12-18 2012-07-20 Boehringer Ingelheim Int Terapia combinada de hcv.
CA2788155C (fr) 2010-01-27 2018-04-24 AB Pharma Ltd. Composes polyheterocycliques hautement puissants en tant qu'inhibiteurs du vhc
US20110312973A1 (en) 2010-03-10 2011-12-22 Bernd Liepold Solid compositions
WO2011150190A2 (fr) 2010-05-26 2011-12-01 Anacor Pharmaceuticals, Inc. Composés inhibiteurs du virus de l'hépatite c (hcv) et leurs procédés d'utilisation
EP2576564A4 (fr) 2010-06-07 2014-01-22 Abbvie Inc Inhibiteurs macrocyclique de la protéase à sérine du virus de l'hépatite c
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
WO2012019299A1 (fr) 2010-08-11 2012-02-16 Boehringer Ingelheim International Gmbh Composés inhibiteurs de l'hépatite c
WO2012037259A1 (fr) 2010-09-15 2012-03-22 Intermune, Inc. Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
TWI523658B (zh) 2010-09-21 2016-03-01 安塔製藥公司 巨環脯胺酸衍生之ｈｃｖ絲胺酸蛋白酶抑制劑
WO2012040040A1 (fr) 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Inhibiteurs de protéase ns3 du vhc
US20120095211A1 (en) 2010-09-22 2012-04-19 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012047764A1 (fr) 2010-10-04 2012-04-12 Intermune, Inc. Peptides antiviraux thérapeutiques
WO2012054874A1 (fr) 2010-10-22 2012-04-26 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la réplication du virus de l'hépatite c
CN103717067A (zh) 2010-12-14 2014-04-09 默沙东公司 制备大环内酰胺的方法与中间体
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
US8957203B2 (en) * 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012166459A1 (fr) 2011-05-27 2012-12-06 Bristol-Myers Squibb Company Tripeptides incorporant du deutérium en tant qu'inhibiteurs du virus de l'hépatite c
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2014001945A (es) 2011-08-19 2014-03-27 Merck Sharp & Dohme Procedimiento e intermedios para la preparacion de macrolactamas.
JP2014530195A (ja) 2011-09-16 2014-11-17 アッヴィ・インコーポレイテッド Ｈｃｖを治療するための方法
WO2013066753A1 (fr) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Compositions utiles pour le traitement de maladies virales
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
US9040479B2 (en) 2012-01-12 2015-05-26 Cocrystal Pharma, Inc. HCV NS3 protease inhibitors
CN102617705B (zh) 2012-02-16 2014-12-31 上海纬诺医药科技有限公司 抑制丙肝病毒复制的大环类化合物
US20130302414A1 (en) 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
TW201408669A (zh) 2012-08-08 2014-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (fr) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014071007A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2914614B1 (fr) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2964664B1 (fr) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c

Also Published As

Publication number Publication date
US20150284391A1 (en) 2015-10-08
LT2909205T (lt) 2016-12-27
ES2613766T3 (es) 2017-05-25
EP2909205B1 (fr) 2016-11-23
PL2909205T3 (pl) 2017-06-30
RS55592B1 (sr) 2017-06-30
JP2015533836A (ja) 2015-11-26
AU2012392557B2 (en) 2017-06-01
JP6154474B2 (ja) 2017-06-28
US9499550B2 (en) 2016-11-22
ZA201503458B (en) 2017-11-29
EP2909205A1 (fr) 2015-08-26
IL238286A0 (en) 2015-06-30
MX360452B (es) 2018-11-01
HRP20161694T1 (hr) 2017-03-10
AU2012392557A1 (en) 2015-06-04
PT2909205T (pt) 2017-02-06
HK1212332A1 (en) 2016-06-10
MX2015004424A (es) 2015-07-06
CY1118729T1 (el) 2017-07-12
NZ708239A (en) 2018-03-23
SMT201700117T1 (it) 2017-03-08
HUE031625T2 (en) 2017-07-28
PH12015500814A1 (en) 2015-06-08
AR088768A1 (es) 2014-07-02
SMT201700117B (it) 2017-03-08
CN104918941A (zh) 2015-09-16
BR112015007879A2 (pt) 2017-07-04
IL238286B (en) 2018-05-31
DK2909205T3 (en) 2017-03-06
CA2888755A1 (fr) 2014-04-24
KR20150074051A (ko) 2015-07-01
TWI570125B (zh) 2017-02-11
WO2014062196A1 (fr) 2014-04-24
SG11201502802PA (en) 2015-05-28
TW201416366A (zh) 2014-05-01
EA201590770A1 (ru) 2015-09-30
EA025560B1 (ru) 2017-01-30
MA37992A1 (fr) 2018-02-28
SI2909205T1 (sl) 2017-02-28

Similar Documents

Publication Publication Date Title
MA37992A1 (fr) Composes inhibiteurs de protéase ns3 pour une utilisation dans le traitement de l’infection par le virus de l'hépatite c.
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
EA201101396A1 (ru) Ингибиторы аутотаксина
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
EA201390155A1 (ru) Комбинации ингибиторов вируса гепатита с
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
GEP20156372B (en) Pyridazinone compounds and their use as daao inhibitors
EA201100879A1 (ru) Производные пиридопиримидина в качестве ингибиторов аутотаксина
MA37756A1 (fr) Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
EA201270656A1 (ru) Ингибиторы вируса гепатита с
EA201500653A1 (ru) Композиции, содержащие триазольное соединение
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
CA2818187C (fr) Inhibiteurs de bromodomaines et leurs utilisations
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA33492B1 (fr) Inhibiteurs de bace
MA35660B1 (fr) Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
UA110612C2 (uk) Похідні 1-аміно-2-циклопропілетилборонової кислоти
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
PH12013502190A1 (en) Hepatitis c virus inhibitors